Gilead Sciences vs Pfizer

Gilead Sciences (GILD), health care, and Pfizer (PFE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Gilead Sciences is worth $210.7B on the stock market and Pfizer $162.8B: Gilead Sciences is valued at 29% more. Over the past year Gilead Sciences's share price has moved +31.8% and Pfizer's +13.4%.

Key facts

Gilead Sciences market value
$210.7B
Pfizer market value
$162.8B
Pfizer P/E
40.8
Gilead Sciences revenue
$29.4BFY to 2025-12-31
Pfizer revenue
$62.6BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Gilead Sciences vs Pfizer: every measure side by side
Measure Gilead Sciences Pfizer
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$210.7Bhigher$162.8Blower
Revenue$29.4Blower$62.6Bhigher
Earnings$8.5Bhigher$7.8Blower
Employees17,000lower75,000higher
Total assets$59Blower$208.2Bhigher
Valuation
P/E—40.8
P/S7.2higher2.6lower
P/B16.2higher1.8lower
Dividend yield1.94%lower7.45%higher
Profitability
Operating margin34.0%—
Balance sheet
Net assets$22.7Blower$86.5Bhigher
Total liabilities$36.4Blower$121.4Bhigher
Total debt$24.9Blower$64.8Bhigher
Cash on hand$7.6Bhigher$1.1Blower
Price change
Today+1.39%higher-1.06%lower
1 year+31.8%higher+13.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Gilead Sciences / Pfizer). Who owns GILD · Who owns PFE

Further comparisons

Learn

Questions and answers

Which is bigger, Gilead Sciences or Pfizer?

By market value, Gilead Sciences is the larger: $210.7B against $162.8B for Pfizer. By revenue in its latest fiscal year, Pfizer is the larger: $62.6B against $29.4B for Gilead Sciences.

Which has the higher dividend yield?

Pfizer: 7.45%, against 1.94% for Gilead Sciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Pfizer: $64.8B, against $24.9B for Gilead Sciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Gilead Sciences and Pfizer?

In their latest 13F filings, Josef Lakonishok holds both.

Cite this page

Funkfolio, “Gilead Sciences vs Pfizer”, data as of 17 November 2026. https://funkfolio.com/compare/gild-vs-pfe

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.